Analysts Offer Predictions for OS Therapies FY2025 Earnings

OS Therapies Inc (NYSE:OSTX) – Stock analysts at Brookline Capital Management cut their FY2025 EPS estimates for shares of OS Therapies in a research note issued to investors on Wednesday, April 2nd. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings per share of ($0.31) for the year, down from their prior forecast of ($0.22). The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share. Brookline Capital Management also issued estimates for OS Therapies’ FY2026 earnings at ($0.34) EPS.

Several other research firms have also recently weighed in on OSTX. Maxim Group increased their price target on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, January 16th. D. Boral Capital reissued a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a research report on Monday. Finally, Lake Street Capital initiated coverage on shares of OS Therapies in a research report on Wednesday, April 2nd. They set a “buy” rating and a $19.00 price target for the company. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $18.00.

OS Therapies Price Performance

OSTX opened at $1.31 on Monday. OS Therapies has a twelve month low of $1.26 and a twelve month high of $7.00. The firm has a 50 day moving average price of $1.70 and a 200-day moving average price of $2.63.

Insider Buying and Selling at OS Therapies

In other OS Therapies news, major shareholder Shalom Auerbach sold 100,000 shares of OS Therapies stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $2.84, for a total transaction of $284,000.00. Following the transaction, the insider now owns 2,431,211 shares of the company’s stock, valued at $6,904,639.24. The trade was a 3.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 13.80% of the stock is currently owned by corporate insiders.

Institutional Trading of OS Therapies

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC boosted its holdings in OS Therapies Inc (NYSE:OSTX) by 120.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the period. CM Management LLC owned 0.51% of OS Therapies worth $471,000 as of its most recent SEC filing.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.